Articles by Daniel Marsh
Bloom Energy Rebounds on Heavy Trading as Insider Sales Surface
Bloom Energy shares climbed 6.2% to $165.39, recovering from a 7.65% drop Friday. The move came after SEC filings revealed significant insider sales by top executives last week.
Bloom Energy Rebounds on Heavy Insider Selling, Wall Street Downgrade
Bloom Energy shares climbed over 6% Monday, recovering from a sharp Friday decline. The move followed SEC filings showing significant insider stock sales by top executives, including the CEO.
MercadoLibre Gains Despite JPMorgan Target Cut Amid Brazil Margin Concerns
MercadoLibre stock edged higher Monday, shrugging off a price target reduction by JPMorgan, which maintained an Overweight rating but flagged competitive margin pressures in Brazil.
MercadoLibre Gains Despite JPMorgan Target Cut Amid Brazil Margin Concerns
MercadoLibre stock advanced 0.9% to $1,773.22 Monday, even as JPMorgan reduced its price target to $2,650, highlighting competitive margin pressures in Brazil. Investors are monitoring inflation and upcoming corporate events.
Travel Stocks Slide on Geopolitical Tensions, Oil Spike
Booking Holdings shares fell alongside the broader travel sector Monday, pressured by surging oil prices and widespread flight cancellations linked to Middle East tensions. The company's 25-for-1 stock split is scheduled for early April.
Travel Stocks Lose $22.6B as Oil Spike, Flight Cancellations Mount
Booking Holdings declined 0.7% as the broader travel sector shed $22.6 billion in market value. The selloff was driven by a 13% spike in oil prices and major flight disruptions linked to Middle East conflict.
AeroVironment Plunges on Downgrade Amid SCAR Contract Uncertainty
AeroVironment shares tumbled almost 19% Monday following a Raymond James downgrade to Underperform, driven by uncertainty over a key U.S. Space Force contract.
AeroVironment Plummets on SCAR Contract Uncertainty, Raymond James Downgrade
AeroVironment shares tumbled almost 19% Monday following a Raymond James downgrade to Underperform. The broker highlighted uncertainty surrounding the U.S. Space Force's $1.4 billion SCAR satellite-communications contract.
Lilly Shares Slip Amid China Drug Approval, Focus on Obesity Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 Monday despite broader market gains. The dip came as Innovent Biologics secured Chinese regulatory clearance for the cancer therapy Jaypirca, a drug developed with Lilly.
Lilly Shares Dip Amid Sector Weakness, Focus on Obesity Drug Pipeline
Eli Lilly shares declined 2.3% to $1,028.07 on Monday, underperforming the broader market. The focus remains on the company's obesity drug pipeline and an upcoming FDA review for its oral GLP-1 candidate, orforglipron.